Morita M, Suzuki K, Yasuda A, Kojima A, Sugimoto M, Watanabe K, Kobayashi H, Kajima K, Hashizume S
Vaccine. 1987 Mar;5(1):65-70. doi: 10.1016/0264-410x(87)90012-0.
Thymidine kinase-negative recombinant vaccinia virus LC16m0 or LC16m8 expressing hepatitis B surface antigen preserved almost the same pathogenicity as their parental thymidine kinase-positive attenuated virus strains. The results demonstrate the potential for using the LC16m0 or LC16m8 virus strain as a vector for recombinant vaccine.